17

April

Basilea licenses late-stage oncology drug candidate derazantinib from ArQule

Basilea Pharmaceutica Ltd. (SIX: BSLN) announced on 4/17/18 that it has entered into a license agreement with ArQule, Inc. (NASDAQ: ARQL) for its oral oncology drug candidate ARQ 087 (derazantinib), which targets the fibroblast growth factor receptor (FGFR) family of kinases.

Read More Here

Janelle

Janelle has blogged 240 posts